GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Flowr Corp (TSXV:FLWR.H) » Definitions » Debt-to-EBITDA

The Flowr (TSXV:FLWR.H) Debt-to-EBITDA : -1.22 (As of Sep. 2022)


View and export this data going back to 2017. Start your Free Trial

What is The Flowr Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Flowr's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was C$0.59 Mil. The Flowr's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was C$9.03 Mil. The Flowr's annualized EBITDA for the quarter that ended in Sep. 2022 was C$-7.90 Mil. The Flowr's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was -1.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for The Flowr's Debt-to-EBITDA or its related term are showing as below:

TSXV:FLWR.H's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

The Flowr Debt-to-EBITDA Historical Data

The historical data trend for The Flowr's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Flowr Debt-to-EBITDA Chart

The Flowr Annual Data
Trend Jun17 Jun18 Dec19 Dec20 Dec21
Debt-to-EBITDA
- - -1.34 -0.41 -0.44

The Flowr Quarterly Data
Sep17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 -0.13 -1.55 -0.34 -1.22

Competitive Comparison of The Flowr's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, The Flowr's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Flowr's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Flowr's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where The Flowr's Debt-to-EBITDA falls into.



The Flowr Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

The Flowr's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(24.59 + 9.144) / -77.256
=-0.44

The Flowr's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.589 + 9.025) / -7.896
=-1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.


The Flowr  (TSXV:FLWR.H) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


The Flowr Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of The Flowr's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


The Flowr (TSXV:FLWR.H) Business Description

Traded in Other Exchanges
N/A
Address
9590 McCarthy Road, Kelowna, BC, CAN, V4V 1R2
The Flowr Corp is a Toronto-headquartered cannabis company with operations in Canada and Europe. Its Canadian operating campus, located in Kelowna, BC, includes a purpose-built, GMP-designed indoor cultivation facility; an outdoor and greenhouse cultivation site; and a R&D facility that is awaiting licensing from Health Canada. From this campus, Flowr produces recreational and medicinal products. Internationally, it intends to service the global medical cannabis market through its subsidiary Holigen, which has a license for cannabis cultivation in Portugal and operates GMP licensed facilities in Portugal.

The Flowr (TSXV:FLWR.H) Headlines

No Headlines